



DISCOVER THE BENEFITS OF TREATING YOUR MEIBOMIAN GLAND DYSFUNCTION (MGD)

**WHAT IS TEARSCIENCE® LIPIFLOW®?
WHAT IS IT ABOUT? WHY IS IT IMPORTANT?
MGD IS A CHRONIC, PROGRESSIVE DISEASE
THAT WILL WORSEN IF NOT TREATED¹**

- As an automated treatment for MGD, **TearScience® LipiFlow®** uses heat and pressure to clear blocked meibomian glands.^{2,3}
- **TearScience® LipiFlow®** significantly improves ocular surface symptoms, including dry eye symptoms and less frequent blurred and/or poor vision.^{4,5}
- Just 1 treatment increases mean gland secretion 3-fold and reduced mean dry eye symptom scores by more than 50%.⁶
- With just a single **TearScience® LipiFlow®** treatment, patients report significant improvements in ability to perform specific tasks such as using computers or digital devices better or longer after treatment.⁷

Johnson&Johnson
MedTech

- Once blockages in glands are cleared, it takes a period of time for your gland oil output to return to normal.
- Results with **TearScience® LipiFlow®** can be experienced up to several weeks after treatment and may vary depending on the severity of the MDG. Results from just one treatment can last up to 12 months.⁶
- Post-treatment, your doctor will check if gland function is improved. On average, patients experience a 3-fold increase in gland secretions within 3 months post-treatment.⁶
- Most patients also experience a significant reduction in dry eye symptoms.⁶ However at times patients have additional ocular surface issues that may contribute to their Dry Eye symptoms, and your doctor may need to prescribe treatments to treat your additional conditions separate from your MGD.

**DON'T FORGET
YOUR APPOINTMENT**

As with any medical procedure, risks and potential complications may occur. Please consult your eye care specialist for detailed information and to discuss these possible risks and complications with you prior to the procedure.

1. Tomlinson A et al. The International Workshop on Meibomian Gland Dysfunction: Report of the Diagnosis Subcommittee. *Invest Ophthalmol Vis Sci*. 2011;52(4):2006-49. REF2019OTH4651.
2. TearScience® LipiFlow® DfU - Doc. 0800-0017, current revision.
3. Information based on internal competitive data and patent analysis as of June 2018 against TearScience and iLux Systems in the US. See iLux website <http://www.tearfilm.com/ilux-device/> and TearCare website <https://sightsscience.com/us/products/tear-care/>. REF2020MLT4004.
4. Lane SS et al. A New System, the TearScience® LipiFlow®, for the Treatment of Meibomian Gland Dysfunction (MGD). *Cornea*. 2012;31(4):396-404. REF2018OTH5003.
5. Murakami D. MGD, treating MGD and its impact on vision quality. Claims Substantiation Memo. Dec. 12, 2019. REF2019TS4124.
6. Blackie CA et al. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. *Clin Ophthalmol*. 2016;10:1385-1396. REF2018TS4059.
7. Blackie CA, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. *Clin Ophthalmol*. 2018;12:169-183. REF2018TS4018.